Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
in rank. This salary range does not include all components of the Department of Pathology faculty compensation program or pay from participation in the Department of Pathology variable compensation
-
Clinical Research Specialist for the Hematologic Malignancies research program. This position will be patient-facing and responsible for implementing clinical research protocols on behalf of the faculty
-
). Following an extensive training program, the Bone Marrow Research Specialist will be assigned a portfolio of cutting-edge Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and other novel therapeutic trials
-
or Associate Professor jointly appointed between the Institute for Genome Sciences (IGS), the Institute for Health Computing (IHC), and the Greenebaum Comprehensive Cancer Center (UMGCCC). Applicants
-
(UMSOP) Department of Practice, Sciences, and Health Outcomes Research (P-SHOR) has an opening for an Administrative Assistant II for the Peer Review Program for Psychiatric Medications. This program is
-
join our Department of Dermatology at the University of Maryland School of Medicine and provide patient care and education within our residency training program. The ideal candidate will have a strong
-
join our Department of Dermatology at the University of Maryland School of Medicine and provide patient care and education within our residency training program. The ideal candidate will have a strong
-
students. * Participate in a program of scholarship. * Contributes to faculty governance and service to the nursing profession. * Other duties as assigned. Hiring Range: $122,000 Benefits Information: UMB
-
, Baltimore School of Pharmacy (UMSOP) Department of Practice, Sciences, and Health Outcomes Research (P-SHOR) has an opening for an Administrative Assistant II for the Peer Review Program for Psychiatric
-
training program, the Bone Marrow Senior Clinical Research Assistant will be assigned a portfolio of cutting-edge Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and other novel therapeutic trials and will